$18.02 -$1.55 (-7.9%)

04:30 PM EST on 01/24/20

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Current Price $18.02 Mkt Cap $5.5B
Open $19.75 P/E Ratio 8.86
Prev. Close $18.02 Div. (Yield) $0.00 (0.0%)
Daily Range $17.92 - $19.80 Volume 4,720,782
52-Wk Range $16.70 - $20.76 Avg. Daily Vol. 3,337,733

Caps

How do you think NASDAQ:EXEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,481 Outperform
95 Underperform
 

All-Star Players

523 Outperform
25 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:EXEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Horsemonkey (79.26)
Submitted January 08, 2018

I often eschew Biotech at this point in history because the investments hinge on single do or die events like FDA approval. It reminds me of a Red OR Black bet on a craps table. That being said Exelixis caught my attention due to its partnerships… More

BRADYstocks (46.33)
Submitted February 26, 2008

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

NASDAQ:EXEL VS S&P 500 (SPY)

Fools bullish on NASDAQ:EXEL are also bullish on:

Fools bearish on NASDAQ:EXEL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EXEL.

Recs

0
Member Avatar wolfhounds (97.94) Submitted: 12/13/2019 2:33:55 PM : Outperform Start Price: $18.06 NASDAQ:EXEL Score: -3.90

Pipeline growth

Recs

0
Member Avatar poluh2k (46.03) Submitted: 11/8/2019 4:56:06 AM : Outperform Start Price: $15.28 NASDAQ:EXEL Score: +11.10

Very good data

Recs

0
Member Avatar genedom (89.34) Submitted: 4/24/2019 2:58:54 PM : Outperform Start Price: $20.73 NASDAQ:EXEL Score: -25.38

potential buyout target. If that happens, the target price could be 30-33. Without buyout, there might be a pushup around June for the ASCO meeting.

Leaderboard

Find the members with the highest scoring picks in EXEL.

Score Leader

beave35

beave35 (91.21) Score: +1,227.95

The Score Leader is the player with the highest score across all their picks in EXEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 12/26/2014 12/5/2019 Outperform 5Y $1.27 +1,318.90% +57.85% +1,261.05 0 Comment
beave35 91.21 12/23/2014 Outperform 5Y $1.30 +1,286.05% +58.09% +1,227.95 0 Comment
tomkao < 20 12/15/2014 Outperform 5Y $1.40 +1,187.14% +63.12% +1,124.02 0 Comment
jack0071 72.03 12/3/2014 Outperform 5Y $1.43 +1,160.14% +58.62% +1,101.52 0 Comment
portefeuille 98.47 12/15/2014 Outperform 5Y $1.44 +1,151.39% +62.80% +1,088.59 0 Comment
akoniec 39.62 10/9/2014 Outperform 3Y $1.55 +1,062.58% +67.48% +995.10 0 Comment
dcoyne13 28.80 9/16/2014 Outperform 5Y $1.62 +1,012.28% +64.49% +947.78 0 Comment
foolerhoff 92.01 1/6/2015 Outperform 5Y $1.64 +998.78% +62.71% +936.07 0 Comment
new2fool23 24.81 1/5/2015 Outperform 1Y $1.67 +979.04% +61.05% +917.99 0 Comment
garisonmp3z < 20 1/5/2015 Outperform 5Y $1.67 +979.04% +61.05% +917.99 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EXEL.